Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

A Phase I Trial of a Pharmacodynamically-Conceived Decitabine and Thioguanine Combination in Patients with Advanced Myeloid Malignancies

Todd Rosenblat, MD, Mark L. Heaney, MD PhD, Joseph G Jurcic, MD, Azra Raza, MD, John G. Mears, MD, Ruth Santos, BS, Diana Carrillo, BS, David Shum, MS, Jacquelyn Gonzales, BSN, RN, Kevin Zikaras, BS, Martin Santos, BS, Rong Zhang, MS, Glorymar Ibanezs, MS, Leah Hogdal, BA, Jennifer Crombie, MD, Hakim Djaballah, PhD, Joseph M. Scandura, MD PhD, Anthony G. Letai, MD PhD, Mark G. Frattini, MD PhD

Blood (2014) 124 (21): 974.

https://doi.org/10.1182/blood.V124.21.974.974

Published: 2014

Journal Articles

Severe Adverse Skin Reaction Used For Sclerodermatous Chronic Graft Versus Host Disease Of The Skin

Caroline Hamm, MD, FRCPC, Sindu M. Kanjeekal, MD, FRCPC, David Shum, Tarek Elfiki, John Mathews

Blood (2013) 122 (21): 5417.

https://doi.org/10.1182/blood.V122.21.5417.5417

Published: 2013

Journal Articles

Preclinical Assessment of a Novel CDC7 Inhibitor: Genomewide RNAi Screening Identifies Unique Synergetic and Resistance Genes,

Nancy Liu-Sullivan, Bhavneet Bhinder, David Shum, Christina Ramirez, Constantin Radu, Hakim Djaballah, PhD, Mark G. Frattini, MD, PhD

Blood (2011) 118 (21): 3570.

https://doi.org/10.1182/blood.V118.21.3570.3570

Published: 2011

Journal Articles

Discovery and Validation of a Novel Class of Small Molecule Inhibitors of the CDC7 Kinase: Modulation of Tumor Cell Growth in Vitro and In Vivo .

Mark G. Frattini, MD, PhD, David Shum, M.S., Kristen M O'Dwyer, M.D., Renier J. Brentjens, MD, PhD, Peter Maslak, MD, Mark Heaney, MD, PhD, Joseph G Jurcic, MD, Hakim Djaballah, Ph.D., Thomas J Kelly, M.D., Ph.D.

Blood (2009) 114 (22): 3771.

https://doi.org/10.1182/blood.V114.22.3771.3771

Published: 2009

Journal Articles

Clinical Implementation of a Novel High-Throughput Screen of Primary Leukemia Cells to Customize Therapy for Relapsed/Refractory Acute Myeloid Leukemia (AML).

Kristen M O'Dwyer, M.D., David Shum, M.S., Mark Heaney, MD, PhD, Renier J. Brentjens, MD, PhD, Peter Maslak, MD, Joseph G Jurcic, MD, Hakim Djaballah, Ph.D., Mark G. Frattini, MD, PhD

Blood (2009) 114 (22): 2657.

https://doi.org/10.1182/blood.V114.22.2657.2657

Published: 2009

Journal Articles

Small Molecule Inhibition of Cdc7, a Key Cell Cycle Regulator and Novel Therapeutic Target, Successfully Inhibits Leukemia Cell Growth in Vitro and in Vivo

Mark G. Frattini, MD, PhD, David Shum, M.S., Kristen M O’Dwyer, M.D., Renier J. Brentjens, MD, PhD, Ray Yeh, Ph.D., Peter Maslak, MD, Mark Lawrence Heaney, MD, PhD, Joseph Jurcic, MD, Hakim Djaballah, Ph.D., Thomas J Kelly, M.D., Ph.D.

Blood (2008) 112 (11): 2668.

https://doi.org/10.1182/blood.V112.11.2668.2668

Published: 2008

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

A Phase I Trial of a Pharmacodynamically-Conceived Decitabine and Thioguanine Combination in Patients with Advanced Myeloid Malignancies

Severe Adverse Skin Reaction Used For Sclerodermatous Chronic Graft Versus Host Disease Of The Skin

Preclinical Assessment of a Novel CDC7 Inhibitor: Genomewide RNAi Screening Identifies Unique Synergetic and Resistance Genes,

Discovery and Validation of a Novel Class of Small Molecule Inhibitors of the CDC7 Kinase: Modulation of Tumor Cell Growth in Vitro and In Vivo .

Clinical Implementation of a Novel High-Throughput Screen of Primary Leukemia Cells to Customize Therapy for Relapsed/Refractory Acute Myeloid Leukemia (AML).

Small Molecule Inhibition of Cdc7, a Key Cell Cycle Regulator and Novel Therapeutic Target, Successfully Inhibits Leukemia Cell Growth in Vitro and in Vivo

Email alerts

ASH Publications

American Society of Hematology

Update search

A Phase I Trial of a Pharmacodynamically-Conceived Decitabine and Thioguanine Combination in Patients with Advanced Myeloid Malignancies

Severe Adverse Skin Reaction Used For Sclerodermatous Chronic Graft Versus Host Disease Of The Skin

Preclinical Assessment of a Novel CDC7 Inhibitor: Genomewide RNAi Screening Identifies Unique Synergetic and Resistance Genes,

Discovery and Validation of a Novel Class of Small Molecule Inhibitors of the CDC7 Kinase: Modulation of Tumor Cell Growth in Vitro and In Vivo .

Clinical Implementation of a Novel High-Throughput Screen of Primary Leukemia Cells to Customize Therapy for Relapsed/Refractory Acute Myeloid Leukemia (AML).

Small Molecule Inhibition of Cdc7, a Key Cell Cycle Regulator and Novel Therapeutic Target, Successfully Inhibits Leukemia Cell Growth in Vitro and in Vivo

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only